6.7.11. symptomatic management metastatic castration-resistant prostate cancer. castration-resistant pca usually debilitating disease often affecting elderly male. multidisciplinary approach required input urologists, medical oncologists, radiation oncologists, nurses, psychologists social workers . critical issues palliation must addressed considering additional systemic treatment, including management pain, constipation, anorexia, nausea, fatigue depression. 6.7.11.1. common complications due bone metastases patients crpc painful bone metastases. external beam rt highly effective, even single fraction . single infusion third generation bisphosphonate could considered rt available . common complications due bone metastases include vertebral collapse deformity, pathological fractures spinal cord compression. cementation effective treatment painful spinal fracture whatever origin, clearly improving pain qol . important offer standard palliative surgery, effective managing osteoblastic metastases . impending spinal cord compression emergency. must recognised early patients educated recognise warning signs. suspected, high-dose corticosteroids must given mri performed soon possible. systematic neurosurgery orthopaedic surgeon consultation planned discuss possible decompression, followed ebrt . otherwise, ebrt with, without, systemic therapy, treatment choice. 6.7.11.2. preventing skeletal-related events 6.7.11.2.1. bisphosphonates zoledronic acid evaluated mcrpc reduce skeletal-related events (sre). study conducted active anti-cancer treatments, docetaxel, available. six hundred forty three patients crpc bone metastases randomised receive zoledronic acid, 4 8 mg every three weeks fiveteen consecutive months, placebo . 8 mg dose poorly tolerated reduced 4 mg show significant benefit. however, fiveteen 24 months follow-up, patients treated 4 mg zoledronic acid fewer sres compared placebo group (44 vs. 33%, p = 0.021) particular fewer pathological fractures (13.1 vs. 22.1%, p = 0.015). furthermore, time first sre longer zoledronic acid group. survival benefit seen prospective trial bisphosphonates. 6.7.11.2.2. rank ligand inhibitors denosumab fully human monoclonal antibody directed rankl (receptor activator nuclear factor κ-b ligand), key mediator osteoclast formation, function, survival. m0 crpc, denosumab associated increased bone-mfs compared placebo (median benefit: 4.2 months, hr: 0.85, p = 0.028) . benefit translate survival difference (43.9 compared 44.8 months, respectively) neither fda ema approved denosumab indication . efficacy safety denosumab (n = 950) compared zoledronic acid (n = 951) patients mcrpc assessed phase iii trial. denosumab superior zoledronic acid delaying preventing sres shown time first on-study sre (pathological fracture, radiation surgery bone, spinal cord compression) 20.7 vs. 17.1 months, respectively (hr: 0.82, p = 0.008). urinary n-telopeptide bone-specific alkaline phosphatase significantly suppressed denosumab arm compared zoledronic acid arm (p < 0.0001 both). however, findings associated survival benefit post-hoc re-evaluation endpoints, denosumab showed identical results comparing sres symptomatic skeletal events . potential toxicity (e.g., osteonecrosis jaw, hypocalcaemia) drugs must always kept mind (5–8.2% m0 crpc mcrpc, respectively) . patients dental examination starting therapy risk jaw necrosis increased several risk factors including history trauma, dental surgery dental infection . also, risk osteonecrosis jaw increased numerically duration use pivotal trial (one year vs. two years denosumab), statistically significant compared zoledronic acid . according ema, hypocalcaemia concern patients treated denosumab zoledronic acid. hypocalcaemia must avoided adequate intake calcium vitamin initiating therapy . hypocalcaemia identified prevented treatment bone protective agents (risk severe hypocalcaemia 8% 5% denosumab zoledronic acid, respectively) . serum calcium measured patients starting therapy monitored treatment, especially first weeks patients risk factors hypocalcaemia medication affecting serum calcium. daily calcium (> 500 mg) vitamin (> 400 iu equivalent) recommended patients, unless case hypercalcaemia .